Following CE Mark in April, HemoSonics Targets Distribution Partners at MEDICA 2017
Charlottesville, VA – October 19, 2017– HemoSonics today announced the appointment of Remi Corlin, a 20-year medical device and diagnostic industry veteran, as VP International Markets to lead the rollout of the Quantra™ Hemostasis Analyzer in markets outside of the US. The Quantra system represents a next-generation point-of-care diagnostic platform that provides actionable information to guide the management of critical bleeding. Clinical evaluations of the Quantra system, which received CE Marking in April, are ongoing in the EU and US. In this role, Corlin will advance HemoSonics’ commercialization efforts of the Quantra system and will engage in distributor discussions at the upcoming MEDICA 2017 conference, November 13-16 in Düsseldorf, Germany.
Corlin was with Haemonetics for 14 years, including eight years as President Asia Pacific during which he was credited with steep and sustained growth, increased market share and establishing coagulation point-of-care testing as a standard practice in China. Following Haemonetics, Corlin was CEO of Virgin Health Bank, a cord blood bank establishing the first stem cell preservation program dedicated to ethnic minorities. Most recently, he founded Strategic Life Sciences Consulting to advise medical technology companies with their commercialization strategies. International distributors interested in learning more about the Quantra system or meeting at MEDICA 2017 should contact Corlin.
“Remi brings a wealth of experience and expertise to our organization as we begin our commercialization efforts for the Quantra system, designed to deliver a new standard of care for the management of bleeding in the critical care setting,” said HemoSonics President and Chief Executive Officer Timothy Fischer.
“It is an exciting time to join the HemoSonics team with the recent clinical and regulatory momentum of the Quantra system,” said Corlin. “I look forward to meeting distributors at MEDICA as we build our commercial organization and begin to forge strong partnerships.”
About the Quantra System
The Quantra system is a rapid, easy-to-use diagnostic platform that utilizes consumable cartridges to run a panel of tests. The initial Surgical Cartridge measures the treatable aspects of coagulation in 15 minutes. The Quantra is designed for use in critical care settings which require that results be generated quickly from an instrument that is easy to operate at the point of care. Recent scientific and clinical data presented at the XXVI International Society on Thrombosis and Hemostasis (ISTH) Congress in Berlin and Euroanaesthesia 2017 demonstrated the excellent analytical performance of the Quantra Surgical Cartridge with the Quantra™ Hemostasis Analyzer and its clinical utility in cardiac surgery and cancer patients.
HemoSonics is a medical device company developing a point-of-care diagnostic platform to guide the management of critical bleeding to improve outcomes and reduce healthcare costs by enabling more targeted transfusion of blood products. The Quantra™ Hemostasis Analyzer is designed to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely information on coagulation status at the point of care. HemoSonics is headquartered in Charlottesville, VA, with research, development and manufacturing facilities in Durham, NC. For more information, visit www.hemosonics.com.
VP International Markets